Ind-Swift Laboratories Ltd
INDSWFTLAB
Company Profile
Business description
Ind-Swift Laboratories Ltd is engaged in the business of manufacturing Active Pharmaceutical Ingredients (API), Intermediates, and formulations. The company caters to diverse therapeutic segments namely Cardiovascular health, Antihistamine, Antidiabetic, Antipsychotic, Parkinson's Disease, Antineoplastic, ADHD Symptoms, Analgesics, Alcohol Abstinence, and Bone Resorption Inhibitor. It operates in a single segment namely, Bulk Drugs and Pharmaceuticals. Geographically, the company caters to both Indian and international markets, of which, maximum revenue is derived from outside India.
Contact
SCO 850, NAC
Shivalik Enclave
Manimajra
ChandigarhPB160101
INDT: +91 1725061850
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 March 2026
Employees
47
Stocks News & Analysis
stocks
We take a different view to market on ASX bloodbath
Sales growth at CSL was lower than expected but streamlining the business has its perks.
stocks
BHP earnings weaker with lower iron ore prices more than offsetting higher copper volumes
Results were softer than expected.
stocks
Moated ASX player makes moves to support growth in China
a2Milk announced an acquisition and a divestiture as it aims to take a bigger slice of China’s baby formula market.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,177.40 | 3.60 | 0.04% |
| CAC 40 | 7,977.25 | 1.83 | -0.02% |
| DAX 40 | 24,360.65 | 62.42 | -0.26% |
| Dow JONES (US) | 44,922.27 | 10.45 | 0.02% |
| FTSE 100 | 9,211.19 | 21.97 | 0.24% |
| HKSE | 25,165.94 | 43.04 | 0.17% |
| NASDAQ | 21,314.95 | 314.82 | -1.46% |
| Nikkei 225 | 42,888.55 | 657.74 | -1.51% |
| NZX 50 Index | 13,071.30 | 142.62 | 1.10% |
| S&P 500 | 6,411.37 | 37.78 | -0.59% |
| S&P/ASX 200 | 8,918.00 | 21.80 | 0.25% |
| SSE Composite Index | 3,766.21 | 38.92 | 1.04% |